Gongshi

Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B

Retrieved on: 
Friday, November 12, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MEL, PK, Safety, Nausea, SITC, Cancer, Private Securities Litigation Reform Act, Squamous cell carcinoma, CMO, Neoplasm, Toxic epidermal necrolysis, Clinical trial, Neuromuscular Disorders, Security (finance), NASDAQ, Appetite, Investor, RCC, Ovarian cancer, Growth, Pembrolizumab, UC, COVID-19, 2021 Essex County Council election, Renal cell carcinoma, Program, Fatigue, Spectrochimica Acta Part B, Risk, Human, Interim, A1, Company, U.S. Securities and Exchange Commission, DRAGON, Large-cell lung carcinoma, Antibody, LinkedIn, SD, Gongshi, NSCLC, Clear cell renal cell carcinoma, Rock, Immunotherapy, Fibrosis, FDA, Alveolar soft part sarcoma, Intellectual property, Pharmaceutical industry, Medical imaging

Details for the virtual e-poster are as follows:

Key Points: 
  • Details for the virtual e-poster are as follows:
    Title: First-in-Human Phase 1 Trial of SRK-181: A Latent TGF1 inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors (DRAGON trial) (#532).
  • Time: Virtual e-posters will be on display on the SITC 2021 virtual meeting platform starting November 12, 2021.
  • Highlights from the DRAGON Part A data presented at SITC include:
    As of September 7, 2021, 29 patients have been dosed in Part A of the trial.
  • The DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in patients with locally advanced or metastatic solid tumors is ongoing.

Scholar Rock to Present at Upcoming Healthcare Conferences

Retrieved on: 
Tuesday, November 2, 2021
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Fibrosis, Rock, LinkedIn, Cancer, Patient, NASDAQ, Investor, View, Conference, Jefferies, Company, Webcast, Credit, Gongshi, Credit Suisse, Neuromuscular Disorders, Pharmaceutical industry, Animal

A live webcast of presentations at the Credit Suisse, Cowen and Jefferies conferences may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com.

Key Points: 

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

Retrieved on: 
Sunday, October 3, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Gongshi, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Spinal muscular atrophy, Clinical trial, ODD, SMA, Serum, Myostatin, Motor neuron, Muscle weakness, SMN, Rock, Risk, Congress, Security (finance), Therapy, European Medicines Agency, Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, FDA, Cancer, Fast Track, Patient, Pathology, LinkedIn, RPD, Gene, Genetic disorder, WCN, Investor, Company, Growth, COVID-19, SMN2, Human, SMN1, TOPAZ, Atrophy, FTD, Safety, Survival, Fibrosis, Orphan drug, EMA, Neuromuscular Disorders, Pharmaceutical industry, Apitegromab, SMA, Scholar Rock, APITEGROMAB, SMA, SCHOLAR ROCK

Time: Virtual e-posters are available for viewing for the duration of the congress (October 3-7, 2021) and will be available on demand for 3 months post conference.

Key Points: 
  • Time: Virtual e-posters are available for viewing for the duration of the congress (October 3-7, 2021) and will be available on demand for 3 months post conference.
  • Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA).
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting

Retrieved on: 
Thursday, September 30, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Gongshi, Food, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, ODD, SMA, Poster, Myostatin, Motor neuron, Hynes Convention Center, Muscle weakness, SMN, Rock, Risk, Security (finance), Therapy, European Medicines Agency, Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, FDA, Cancer, Fast Track, Patient, Pathology, Annual general meeting, LinkedIn, Hynes Convention Center station, Gene, RPD, Genetic disorder, Investor, Company, Growth, COVID-19, SMN2, Human, SMN1, Atrophy, FTD, Safety, Survival, Fibrosis, Orphan drug, EMA, Neuromuscular Disorders, Pharmaceutical industry, Apitegromab, SMA, Scholar Rock, APITEGROMAB, SMA, SCHOLAR ROCK

Scholar Rock will have a physical booth (#915) at the Hynes Convention Center, Exhibit Halls C & D, as well as a virtual booth at the meeting.

Key Points: 
  • Scholar Rock will have a physical booth (#915) at the Hynes Convention Center, Exhibit Halls C & D, as well as a virtual booth at the meeting.
  • Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA).
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

 Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Retrieved on: 
Thursday, September 23, 2021
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Gongshi, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Spinal muscular atrophy, Scoliosis, Clinical trial, SMA, Myostatin, Motor neuron, Muscle weakness, ODD, SMN, Rock, Risk, Security (finance), Therapy, European Medicines Agency, NASDAQ, FDA, Cancer, BST, Fast Track, Patient, Pathology, Poster, LinkedIn, RPD, Gene, Genetic disorder, WMS, Private Securities Litigation Reform Act, Investor, Company, Growth, COVID-19, SMN2, Human, TOPAZ, SMN1, Atrophy, FTD, Safety, Survival, Fibrosis, Orphan drug, EMA, Neuromuscular Disorders, Pharmaceutical industry, Medicine, Vaccine, Medical imaging, Apitegromab, SMA, Scholar Rock, APITEGROMAB, SMA, SCHOLAR ROCK

Greater increases in HFMSE (non-ambulatory) and Revised Hammersmith Scale (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures.

Key Points: 
  • Greater increases in HFMSE (non-ambulatory) and Revised Hammersmith Scale (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures.
  • Virtual poster presentations (LBP.10 and EP.277) on September 23, 2021, at 16:30-18:30 BST
    E-Posters available to view on demand and exhibition area open starting Monday, September 20, 2021.
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference

Retrieved on: 
Wednesday, September 22, 2021
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Anemia, Neuromuscular Disorders, View, Investor, Gongshi, NASDAQ, Conference, Cancer, Company, Webcast, Patient, Fibrosis, LinkedIn, Rock, Vaccine

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29th, 2021 at 11:20 a.m.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29th, 2021 at 11:20 a.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005707/en/

Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

Retrieved on: 
Monday, August 16, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Psychology, Multimedia, NASDAQ, U.S. Securities and Exchange Commission, Novartis, HR, Company, Finance Secretary (India), Risk, Private Securities Litigation Reform Act, LinkedIn, Gongshi, COVID-19, Seton Hall University, Investor, Research, Acquisition, List of counseling topics, Biotechnology, Security (finance), Patient, Holy Name Medical Center, Country, Leadership, Fibrosis, Neuromuscular Disorders, Cancer, Anemia, Industry, Rock, Risk management

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer.
  • View the full release here: https://www.businesswire.com/news/home/20210816005424/en/
    Caryn Parlavecchio, Chief Human Resources Officer at Scholar Rock (Photo: Business Wire)
    Caryns substantial industry knowledge and extensive leadership experience developing and implementing HR strategies, talent acquisition, and diversity and inclusion will be critical in guiding Scholar Rocks accelerated growth plans, said Nagesh Mahanthappa, Ph.D. Interim CEO of Scholar Rock.
  • I am excited to join Scholar Rock and be a part of this talented and fast-growing team that is dedicated to moving our programs forward to address unmet medical needs, said Parlavecchio.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK

Retrieved on: 
Saturday, August 14, 2021
News, Company, NASDAQ, Gongshi, GLOBE, Private investigator

NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation (Scholar Rock or the Company) (NASDAQ:SRRK).

Key Points: 
  • NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation (Scholar Rock or the Company) (NASDAQ:SRRK).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Scholar Rock and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, August 10, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Gongshi, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Business operations, Food, Conference, Cancer, Private Securities Litigation Reform Act, Spinal muscular atrophy, TOPAZ, Growth, Type, European Medicines Agency, BLA, PRIME, Company, U.S. Securities and Exchange Commission, Fast Track, CFO, Risk, WHO, Nusinersen, Squamous cell carcinoma, Interim, Pharmacokinetics, Population, Myostatin, NASDAQ, Research, Large-cell lung carcinoma, LinkedIn, Review, Fibrosis, Cure, Human, Security (finance), Part, Investor, FDA, Rock, DRAGON, World Health Organization, Neuromuscular Disorders, Johns Hopkins School of Medicine, Clinical trial, COVID-19, Biologics license application, Pharmaceutical industry, Lithium

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the second quarter ended June 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the second quarter ended June 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.
  • Research and development expense was $25.6 million for the quarter ended June 30, 2021 compared to $17.0 million for the quarter ended June 30, 2020.
  • General and administrative expense was $9.3 million for the quarter ended June 30, 2021 compared to $6.4 million for the quarter ended June 30, 2020.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK

Retrieved on: 
Friday, August 6, 2021
Company, NASDAQ, News, GLOBE, Gongshi, Private investigator

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation (Scholar Rock or the Company) (NASDAQ:SRRK).

Key Points: 
  • NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation (Scholar Rock or the Company) (NASDAQ:SRRK).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Scholar Rock and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.